CREBBP/EP300 gene mutations frequently occur in hematological malignancies through a variety of different mechanisms, resulting in poor patient prognosis, including worse overall survival (OS), progression-free survival (PFS), and event-free survival (EFS) [37,38,39,40,41]. Here, CREBBP is linked to hematologic disorder.